Form 4: KalVista Pharmaceuticals CEO Benjamin Palleiko Reports Stock Transactions

CEO Benjamin Palleiko reports the vesting of restricted stock units and performance stock units, along with sales to cover tax obligations.

Summary

• On May 17, 2025, Benjamin Palleiko, CEO of KalVista Pharmaceuticals, exercised restricted stock units (RSUs) and performance stock units (PSUs), acquiring 9,364 shares.
• Following this transaction, Palleiko directly owns 297,175 shares of common stock.
• On May 19, 2025, Palleiko sold 3,808 shares at a price of $11.8428 per share to cover tax withholding obligations related to the vesting of the RSUs and PSUs.
• After the sale, Palleiko directly owns 293,367 shares of common stock.
• Palleiko also holds 9,675 RSUs and 13,889 RSUs after the reported transactions.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the trading activities of company executives. It's a standard practice for publicly traded companies and their officers.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
• Similar filings are common among pharmaceutical companies like BioCryst Pharmaceuticals and Ionis Pharmaceuticals, where stock-based compensation is a significant part of executive pay.
• The 'sell to cover' transaction for tax obligations is a typical method used by executives to manage their equity compensation.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares, but the overall impact is likely minimal as it is related to tax obligations.

Key Dates

Keywords

KalVista Pharmaceuticals, Benjamin Palleiko, Form 4, stock, RSU, PSU, insider trading, vesting, tax withholding, securities